Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Share-based Compensation (2016 - 2025)

United Therapeutics (UTHR) has disclosed Share-based Compensation for 17 consecutive years, with $39.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 44.44% to $39.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $147.7 million through Dec 2025, up 2.57% year-over-year, with the annual reading at $147.7 million for FY2025, 2.57% up from the prior year.
  • Share-based Compensation hit $39.0 million in Q4 2025 for United Therapeutics, roughly flat from $39.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $65.5 million in Q2 2022 to a low of -$21.1 million in Q1 2022.
  • Historically, Share-based Compensation has averaged $28.8 million across 5 years, with a median of $30.4 million in 2021.
  • Biggest five-year swings in Share-based Compensation: plummeted 152.62% in 2022 and later surged 979.17% in 2023.
  • Year by year, Share-based Compensation stood at $44.7 million in 2021, then soared by 44.97% to $64.8 million in 2022, then tumbled by 74.38% to $16.6 million in 2023, then soared by 62.65% to $27.0 million in 2024, then surged by 44.44% to $39.0 million in 2025.
  • Business Quant data shows Share-based Compensation for UTHR at $39.0 million in Q4 2025, $39.1 million in Q3 2025, and $37.8 million in Q2 2025.